People with lactose intolerance may have decreased risk of breast, lung, and ovarian cancers
the ONA take:
According to a new study published in the journal Nature, researchers from Lung University and Region Skane in Sweden have found that people who are lactose intolerant have a decreased risk for developing breast, lung, and ovarian cancers.
For the study, researchers sought to investigate the possible association between dairy products and the development of cancer. To do so, they designed the study to determine whether low consumption of dairy products in people with lactose intolerance decreases their risk for developing breast, lung, and ovarian cancers.
The researchers identified nearly 23,000 individuals with lactose intolerance from two Swedish national registers. They found that the risks for developing any of the three cancers was significantly lower in people with lactose intolerance compared with to people without lactose intolerance. Incidence rates were similar across different genders and countries of birth.
The researchers also looked at the siblings and parents of those with lactose intolerance and found their risks for developing breast, lung, and ovarian cancers were similar to those of the general population. The findings suggest that patients with lactose intolerance may have a lower risk for those cancers as a result of their diet. The researchers note that the study does not prove cause and effect and further studies are warranted to explain this study's results.
People who are lactose intolerant have a decreased risk for developing breast, lung, and ovarian cancers.
Previous studies have shown that there are large differences in breast and ovarian cancer incidence across different areas of the globe. Experts know, for instance, that the highest incidence of breast and ovarian cancer is in North America, Western Europe and Scandinavia, while incidence is lowest in East and Central Africa.
Twin studies and studies of immigrants have suggested that these differences in incidence are due to environmental factors rather than genetic or ethnic differences.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|